Citadel Advisors
EGRX

Citadel Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Citadel Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26,013
Closed -$97K – 15776
2024
Q3 		$97K Buy
+26,013
New +$124K ﹤0.01% 11150
2024
Q2 		– Sell
-43,729
Closed -$229K – 15697
2024
Q1 		$229K Sell
43,729
-28,170
-39% -$155K ﹤0.01% 10047
2023
Q4 		$376K Sell
71,899
-220,261
-75% -$2.17M ﹤0.01% 8693
2023
Q3 		$4.61M Sell
292,160
-101,389
-26% -$1.82M ﹤0.01% 3787
2023
Q2 		$7.65M Buy
393,549
+240,445
+157% +$5.7M ﹤0.01% 3036
2023
Q1 		$4.34M Buy
153,104
+39,403
+35% +$1.17M ﹤0.01% 4040
2022
Q4 		$3.32M Sell
113,701
-71,360
-39% -$2.27M ﹤0.01% 4571
2022
Q3 		$4.89M Buy
185,061
+119,741
+183% +$4.39M ﹤0.01% 3910
2022
Q2 		$2.9M Buy
65,320
+17,359
+36% +$797K ﹤0.01% 4814
2022
Q1 		$2.37M Buy
47,961
+26,856
+127% +$1.29M ﹤0.01% 5714
2021
Q4 		$1.07M Sell
21,105
-24,989
-54% -$1.29M ﹤0.01% 7773
2021
Q3 		$2.57M Sell
46,094
-3,422
-7% -$168K ﹤0.01% 5739
2021
Q2 		$2.12M Sell
49,516
-40,061
-45% -$1.65M ﹤0.01% 6469
2021
Q1 		$3.74M Sell
89,577
-145,422
-62% -$6.75M ﹤0.01% 4926
2020
Q4 		$10.9M Sell
234,999
-88,957
-27% -$4.16M ﹤0.01% 2521
2020
Q3 		$13.8M Buy
323,956
+128,078
+65% +$5.6M ﹤0.01% 1928
2020
Q2 		$9.4M Buy
195,878
+188,085
+2,414% +$9.38M ﹤0.01% 2295
2020
Q1 		$358K Buy
7,793
+4,197
+117% +$211K ﹤0.01% 7019
2019
Q4 		$216K Sell
3,596
-48,801
-93% -$2.91M ﹤0.01% 8065
2019
Q3 		$2.96M Sell
52,397
-351
-0.7% -$19.7K ﹤0.01% 3856
2019
Q2 		$2.94M Sell
52,748
-19,256
-27% -$1M ﹤0.01% 3890
2019
Q1 		$3.63M Buy
72,004
+32,419
+82% +$1.44M ﹤0.01% 3453
2018
Q4 		$1.59M Sell
39,585
-258,954
-87% -$13.3M ﹤0.01% 4521
2018
Q3 		$20.7M Buy
298,539
+25,733
+9% +$1.95M 0.01% 1359
2018
Q2 		$20.6M Sell
272,806
-97,990
-26% -$6.16M 0.01% 1284
2018
Q1 		$19.5M Buy
370,796
+296,327
+398% +$17.2M 0.01% 1139
2017
Q4 		$3.98M Buy
+74,469
New +$4.14M ﹤0.01% 2745
2017
Q3 		– Sell
-28,204
Closed -$1.71M – 8168
2017
Q2 		$2.23M Buy
28,204
+13,340
+90% +$1.09M ﹤0.01% 3044
2017
Q1 		$1.23M Sell
14,864
-106,171
-88% -$7.89M ﹤0.01% 3715
2016
Q4 		$9.6M Buy
121,035
+7,265
+6% +$528K 0.01% 1391
2016
Q3 		$7.96M Sell
113,770
-128,189
-53% -$7.1M 0.01% 1565
2016
Q2 		$9.38M Buy
241,959
+231,881
+2,301% +$9.66M 0.01% 1295
2016
Q1 		$408K Sell
10,078
-12,124
-55% -$769K ﹤0.01% 4688
2015
Q4 		$1.97M Buy
22,202
+17,199
+344% +$1.36M ﹤0.01% 2759
2015
Q3 		$370K Sell
5,003
-23,292
-82% -$1.94M ﹤0.01% 5256
2015
Q2 		$2.29M Buy
28,295
+21,893
+342% +$1.43M ﹤0.01% 2913
2015
Q1 		$268K Buy
+6,402
New +$182K ﹤0.01% 5812

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Citadel Advisors's EGRX Position: Q4 2024 in Review

Citadel Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 26,013 shares — an estimated $97K sold.

Citadel Advisors first reported a position in EGRX in Q1 2015 and held it in 37 quarters. The position peaked at $20.7M in Q3 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Citadel Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 26,013 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $97K.
  • Citadel Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 37 quarters.
  • Citadel Advisors's Eagle Pharmaceuticals, Inc. position peaked at $20.7M in Q3 2018.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.